quinazolines has been researched along with staurosporine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Arkin, H; Holland, JF; Ohnuma, T; Schwartz, GK | 1 |
| App, H; Chen, I; Chen, J; Gazit, A; Hirth, P; Levitzki, A; McMahon, G | 1 |
| Lavelle, F | 1 |
| Elbaum, D; Lydon, NB; Toledo, LM | 1 |
| del Carmen Medina, L; García-Sáinz, JA; Vázquez-Prado, J | 1 |
| Aharony, D; Bhat, RV; Folmer, JJ; Frazee, WJ; Ghanekar, SV; Jacobs, RT; Scott, CW; Sobotka-Briner, C; Wilkins, DE | 1 |
| Baba, K; Fujiwara, H; Kariya, T; Kawai, T; Minatoguchi, S; Takahashi, M; Takemura, G; Uno, Y; Zhang, C | 1 |
| Ikejima, T; Onodera, S; Tashiro, S; Wang, C; Wang, MW | 2 |
| Kiyoi, H | 4 |
| Marais, R; Niculescu-Duvaz, D; Springer, C; Whittaker, S | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Ehninger, G; Illmer, T | 1 |
| Gary Gilliland, D; Tam, WF | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Mologni, L | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL | 1 |
| Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X | 1 |
| Bai, Y; Bennett, K; Colinge, J; Eschrich, S; Fang, B; Grebien, F; Haura, EB; Kim, JY; Koomen, J; Li, J; Okamoto, I; Qian, X; Rawal, B; Rix, U; Schell, M; Song, L; Stukalov, A; Superti-Furga, G; Winter, G; Yoshida, T; Zhang, G | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Alam, KA; Engh, RA; Gani, OASBM | 1 |
8 review(s) available for quinazolines and staurosporine
| Article | Year |
|---|---|
The structure-based design of ATP-site directed protein kinase inhibitors.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Anthraquinones; Binding Sites; Catalytic Domain; Cyclin-Dependent Kinases; Drug Design; Enzyme Inhibitors; Humans; Kinetin; Piperazines; Protein-Tyrosine Kinases; Purines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Growth Factor; Roscovitine; Staurosporine; Structure-Activity Relationship | 1999 |
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
[Novel molecularly target therapies for leukemia].
Topics: Antineoplastic Agents; Carbazoles; Farnesyltranstransferase; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia; Piperazines; Quinazolines; Staurosporine | 2007 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Can FLT3 inhibitors overcome resistance in AML?
Topics: Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Piperazines; Quinazolines; Staurosporine | 2008 |
[FLT3 kinase inhibitors for the treatment of acute leukemia].
Topics: Acute Disease; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia; Mutation; Piperazines; Quinazolines; Signal Transduction; Staurosporine | 2010 |
Development of RET kinase inhibitors for targeted cancer therapy.
Topics: Antineoplastic Agents; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Quinazolines; Staurosporine; Urea | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
18 other study(ies) available for quinazolines and staurosporine
| Article | Year |
|---|---|
Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate.
Topics: Alkaloids; Cell Division; Drug Resistance; Humans; In Vitro Techniques; Leukemia, Lymphoid; Protein Kinase C; Quinazolines; Staurosporine; Tetradecanoylphorbol Acetate; Trimetrexate; Tumor Cells, Cultured | 1991 |
Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.
Topics: Aniline Compounds; ErbB Receptors; Phosphorylation; Protein Kinase C; Quinazolines; Staurosporine; Structure-Activity Relationship | 1996 |
[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?].
Topics: Animals; ErbB Receptors; Humans; In Vitro Techniques; Male; Mice; Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Rats; Staurosporine; Structure-Activity Relationship | 1997 |
Cross-talk between receptors with intrinsic tyrosine kinase activity and alpha1b-adrenoceptors.
Topics: Adrenergic alpha-Agonists; Androstadienes; Animals; Cell Line; Cell Membrane; Cricetinae; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Fibroblasts; Guanosine 5'-O-(3-Thiotriphosphate); Indoles; Norepinephrine; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Platelet-Derived Growth Factor; Protein Binding; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Adrenergic, alpha-1; Staurosporine; Time Factors; Transfection; Tyrphostins; Wortmannin | 2000 |
Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis.
Topics: Aniline Compounds; Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Cell Line; Coloring Agents; DNA Fragmentation; Enzyme Inhibitors; Fluorescent Dyes; Humans; In Situ Nick-End Labeling; Kinetics; Nerve Growth Factor; PC12 Cells; Phenotype; Quinazolines; Rats; Recombinant Proteins; Staurosporine; Structure-Activity Relationship; Swine | 2003 |
Alpha1-receptor or adenosine A1-receptor dependent pathway alone is not sufficient but summation of these pathways is required to achieve an ischaemic preconditioning effect in rabbits.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Enzyme Inhibitors; Heart Rate; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Protein Kinase C; Quinazolines; Rabbits; Receptor, Adenosine A1; Receptors, Adrenergic, alpha-1; Staurosporine; Theophylline; Tyramine; Vasodilator Agents | 2005 |
Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death.
Topics: Androstadienes; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Enzyme Inhibitors; Evodia; Gene Expression; Genes, p53; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; MAP Kinase Signaling System; Melanoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phytotherapy; Plant Extracts; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Sirtuin 1; Sirtuins; Staurosporine; Wortmannin | 2005 |
[Effect of protein kinase C on human melanoma A375-S2 cell death induced by evodiamine].
Topics: Apoptosis; Cell Line, Tumor; Evodia; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Melanoma; Plant Extracts; Plants, Medicinal; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Staurosporine | 2005 |
[The present status of, and problems with the development of FLT3 kinase inhibitors].
Topics: Adult; Cell Cycle Proteins; Chaperonins; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Mutation; Piperazines; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Staurosporine | 2006 |
The EGF receptor Hokey-Cokey.
Topics: Antineoplastic Agents; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine | 2012 |
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Topics: Acrylamides; Amino Acid Substitution; Animals; Area Under Curve; Base Sequence; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; RNA Interference; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Quinazolines; Staurosporine | 2013 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
Inhibitor binding to mutants of protein kinase A with GGGxxG and GxGxxA glycine-rich loop motifs.
Topics: Adenosine Triphosphate; Amino Acid Motifs; Amino Acid Substitution; Binding Sites; Cyclic AMP-Dependent Protein Kinases; Glycine; Mutation; Protein Kinase Inhibitors; Quinazolines; Staurosporine; Surface Plasmon Resonance | 2021 |